Business Wire

FINN-GRACE-VENTURES

Share
Finn Grace Ventures Secures up to €100 Million Investment Commitment from GEM Group

Finn Grace Ventures (“FGV”), is pleased to announce that it has signed an agreement with GEM Global Yield LLC SCS ("GEM"), for the investment commitment of up to €100 million into FGV over the period of next 36 months through a Share Subscription Facility.

FGV will use the funds to strengthen its business through its subsidiaries in European Union (“EU”) especially in Austria and other European countries such as France, Germany, Hungary, etc., by funding theirs development and business expansion activities, with the objective of becoming a market leader in Internet Communication Technology business. FGV have signed memorandum with several tech startup companies in European Union region.

The capital commitment will allow FGV to drawdown the funds during the 3-years term by issuing shares of FGV's common stock to GEM Group and subject to share lending arrangement(s) being in place. FGV’s aims to invest more into startup companies in European Union region.

FGV will control the timing and maximum amount of drawdown under this facility and has no minimum drawdown obligation. Concurrent with a public listing of FGV shares, FGV will issue warrants to GEM to purchase up to ten percent (10%) of the outstanding common stock of the FGV on a fully diluted basis. The warrants will have an exercise price per share equal to the Closing Bid Price of the Shares on the first day of trading upon the completion of Go Public Transaction.

About Finn Grace Ventures

Finn Grace Ventures Limited is primarily a Venture Capital Holding Corporation. Incorporated in the UK, FGV has invested in multiple and diverse business ventures. Furthermore, FGV continues to look out for and invests in start-ups, business ventures and private companies that manifest double digit growth and provide a clear and present added value to the ecosystem. FGV’s interests span across the globe from as far as Indonesia to investments in Europe and the United States. Their principal place of business is located in London, Vienna, Paris and Jakarta.

About GEM Group

Global Emerging Markets (“GEM”) is a $3.4 billion alternative investment group that manages a diverse set of investment vehicles focused on emerging markets across the world. GEM’s investment vehicles provide the group and its investors with a diversified portfolio of asset classes that span the global private investing spectrum. Each investment vehicle has a different degree of operational control, risk-adjusted return and liquidity profile. Its family of funds and investment vehicles provide GEM and its partners with exposure to: Small-Mid Cap Management Buyouts, Private Investments in Public Equities (PIPEs) and select venture investments.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer22.1.2026 14:00:00 CET | Press release

Data demonstrate a 35 percent reduction in the risk of death Both dual primary endpoints (progression-free and overall survival) were met, without the need for biomarker selection and without increased safety burden Relacorilant’s New Drug Application (NDA) is under review by the U.S. Food and Drug Administration (FDA) as a treatment for patients with platinum-resistant ovarian cancer with a Prescription Drug User Fee Act (PDUFA) target action date of July 11, 2026 Relacorilant’s Marketing Authorization Application (MAA) for patients with platinum-resistant ovarian cancer is also under review by the European Medicines Agency (EMA) Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that ROSELLA, the company’s pivotal Phase 3 trial of relacorilant plus nab-paclitax

ExaGrid Announces All Flash/SSD Tiered Backup Storage Solution22.1.2026 14:00:00 CET | Press release

ExaGrid’s new solution offers the fastest, most scalable, and most secure backups in the industry ExaGrid®, the industry’s only Tiered Backup Storage solution with AI-Powered Retention Time-Lock (RTL) that includes a non-network-facing tier (tiered air gap), Auto Detect & Guard, delayed deletes and immutability for ransomware recovery, today announced that it is shipping an All Flash/SSD backup storage solution with a unique front-end Landing Zone and non-network-facing Repository Tier (tiered air gap) that stores all backup retention using advanced data deduplication. The new SSD appliances ship with ExaGrid software version 8. ExaGrid’s unique Landing Zone and scale-out architecture allow for significantly faster backups and restores, as well as scalability as data grows, versus other SSD products such as Dell Data Domain inline deduplication appliances with SSD or straight SSD from Pure Storage. Due to three years of software work and the extremely fast performance of SSD, ExaGrid’s

Parse Biosciences Launches Workflow for Immune Repertoire and Transcriptome Analysis22.1.2026 14:00:00 CET | Press release

New Trailmaker functionality integrates immune repertoire and whole transcriptome data to deliver rapid, publication-ready insights Parse Biosciences, the leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of a fully integrated immune repertoire and whole transcriptome analysis workflow in its data analysis platform, Trailmaker™. The new functionality complements Parse’s existing portfolio of Evercode immune products to enable a full end-to-end workflow for researchers. Immunologists have lacked an integrated, purpose-built platform capable of connecting immune repertoire data with whole transcriptome single cell insights. As a result, interpreting clonal behavior, understanding functional cell states, and drawing meaningful biological conclusions has often required stitching together fragmented tools, custom code, or inconsistent visualization approaches. The new Trailmaker functionality directly addresses these challenges by provi

AMGTA Announces EOS as New Principal Member and Appoints Björn Hannappel to Board of Directors22.1.2026 13:59:00 CET | Press release

The Additive Manufacturer Green Trade Association (AMGTA) today announced that EOS has elevated its longstanding participation in the association to Principal Member. As part of this expanded leadership role, Björn Hannappel, Head of Sustainability at EOS, has joined the AMGTA Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121601881/en/ Björn Hannappel, Head of Sustainability at EOS, has joined the AMGTA Board of Directors. Principal Membership represents AMGTA’s highest level of engagement and is reserved for organizations demonstrating sustained leadership, strategic alignment, and a commitment to advancing sustainable and resilient manufacturing practices globally. As a Principal Member, EOS will take on an expanded role in shaping AMGTA’s strategic direction, governance, and industry collaboration initiatives. EOS is a world-leading technology supplier in the field of commercial 3D printing of meta

EV Group Strengthens Its European Presence With the Acquisition of Cornelius Polska22.1.2026 13:19:00 CET | Press release

Eigenmann & Veronelli Group (“EV Group”), a leading distributor and manufacturer of specialty chemicals and food ingredients, has signed an agreement to acquire the majority shareholding in Cornelius Polska. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122961168/en/ Photographed (left to right): Ludovico Balbo di Vinadio, Shareholder and Deputy Chairman, EV Group; Piotr Wasilewski, General Manager, Cornelius Polska Sp. z. o. o.; Cristina Colombo, Chief Financial Officer, EV Group; Dr Neville Prior, Group Chairman, Cornelius Group plc; Gabriele Bonomi, Chief Executive Officer, EV Group Established in Poland in 2007 and headquartered in Warsaw, Poland, Cornelius Polska is a well‑established distributor of specialty chemicals, serving as a key partner to international suppliers, and a broad and diverse customer base. With operations firmly rooted in Poland, the company is active in the beauty & personal care, food, and sev

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye